Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Baseline and early functional immune response is associated with subsequent clinical outcomes of PD-1 inhibition therapy in metastatic melanoma patients.
Gérard A, Doyen J, Cremoni M, Bailly L, Zorzi K, Ruetsch-Chelli C, Brglez V, Picard-Gauci A, Troin L, Esnault VLM, Passeron T, Montaudié H, Seitz-Polski B. Gérard A, et al. Among authors: picard gauci a. J Immunother Cancer. 2021 Jun;9(6):e002512. doi: 10.1136/jitc-2021-002512. J Immunother Cancer. 2021. PMID: 34088741 Free PMC article. Clinical Trial.
Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study.
Montaudié H, Viotti J, Combemale P, Dutriaux C, Dupin N, Robert C, Mortier L, Kaphan R, Duval-Modeste AB, Dalle S, De Quatrebarbes J, Stefan A, Brunet-Possenti F, Kogay M, Picard-Gauci A, Poissonnet G, Peyrade F. Montaudié H, et al. Oncotarget. 2020 Jan 28;11(4):378-385. doi: 10.18632/oncotarget.27434. eCollection 2020 Jan 28. Oncotarget. 2020. PMID: 32064041 Free PMC article.
Correction to: ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity.
Cheli Y, Tulic MK, El Hachem N, Nottet N, Jacquel A, Gesson M, Strub T, Bille K, Picard-Gauci A, Montaudié H, Beranger GE, Passeron T, Close P, Bertolotto C, Ballotti R. Cheli Y, et al. Among authors: picard gauci a. Mol Cancer. 2021 Jan 27;20(1):21. doi: 10.1186/s12943-021-01319-5. Mol Cancer. 2021. PMID: 33504341 Free PMC article. No abstract available.
Association of TRF2 expression and myeloid-derived suppressor cells infiltration with clinical outcome of patients with cutaneous melanoma.
Ilié M, Lantéri E, Chamorey E, Thamphya B, Hamila M, Montaudié H, Picard-Gauci A, Gardrat S, Passeron T, Lassalle S, Long-Mira E, Cherfils-Vicini J, Gilson E, Hofman V, Hofman P. Ilié M, et al. Among authors: picard gauci a. Oncoimmunology. 2021 Mar 19;10(1):1901446. doi: 10.1080/2162402X.2021.1901446. Oncoimmunology. 2021. PMID: 33796413 Free PMC article.
Comparison of Two Rapid Assays for the Detection of BRAF V600 Mutations in Metastatic Melanoma including Positive Sentinel Lymph Nodes.
Long-Mira E, Picard-Gauci A, Lassalle S, Hofman V, Lalvée S, Tanga V, Zahaf K, Bonnetaud C, Lespinet V, Camuzard O, Montaudié H, Poissonnet G, Passeron T, Ilié M, Hofman P. Long-Mira E, et al. Among authors: picard gauci a. Diagnostics (Basel). 2022 Mar 19;12(3):751. doi: 10.3390/diagnostics12030751. Diagnostics (Basel). 2022. PMID: 35328303 Free PMC article.
Pathological complete response to neoadjuvant pembrolizumab in a patient with metastatic cutaneous squamous cell carcinoma.
Blaise M, Poissonnet G, Cardot-Leccia N, Sudaka A, Velin M, Chassang M, Razzouk-Cadet M, Picard-Gauci A, Passeron T, Montaudié H. Blaise M, et al. Among authors: picard gauci a. J Eur Acad Dermatol Venereol. 2023 Nov;37(11):e1318-e1320. doi: 10.1111/jdv.19307. Epub 2023 Jul 11. J Eur Acad Dermatol Venereol. 2023. PMID: 37415448 No abstract available.
12 results